LGND - Ligand Pharmaceuticals Non-GAAP EPS of $0.76 beats by $0.10 revenue of $45.69M beats by $11.48M
Ligand Pharmaceuticals press release (NASDAQ:LGND): Q1 Non-GAAP EPS of $0.76 beats by $0.10. Revenue of $45.69M (-17.2% Y/Y) beats by $11.48M. Outlook: Ligand is reaffirming 2022 revenue guidance for the combined business and providing revenue estimated to be attributable to the OmniAb business anticipating the spin-off later this year. Ligand expects 2022 royalties of $55 million to $60 million, Captisol sales of $40 million to $50 million and contract revenue of $52 million to $62 million. These revenue components result in total revenue of $147 million to $172 million for the combined business. The company expects that $35 million to $45 million of revenue will be attributable to OmniAb, principally in the contract revenue line.
For further details see:
Ligand Pharmaceuticals Non-GAAP EPS of $0.76 beats by $0.10, revenue of $45.69M beats by $11.48M